Trastuzumab is an FDA-approved treatment for HER2-positive breast cancer that reduces HER2 overactivity through various mechanisms, including preventing HER2 dimerization, downregulating the HER2 receptor via endocytic destruction, and inhibiting HER2 cleavage by metalloproteases [2]. Here, ERBB2 is linked to breast carcinoma.